Study Purpose:
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of long-term use of high fat/high calorie and high calorie diets in people with amyotrophic lateral sclerosis (ALS) (Lou Gehrig's disease).Study Status:
Not recruiting
Disease:
Amyotrophic Lateral Sclerosis
Study Type:
Interventional
Type of Intervention:
Dietary Supplement
Intervention Name:
Oxepa, Jevity 1.5, Jevity 1.0
Placebo:
Phase:
Phase 2
Study Chair(s)/Principal Investigator(s):
Anne-Marie A Wills, M.D., Massachusetts General Hospital
Clinicaltrials.gov ID:
Neals Affiliated?
Yes
Coordinating Center Contact Information
Massachusetts General Hospital
149 13th Street
Charlestown, Massachusetts, 02129 United States
Full Study Summary:
Weight loss is a common and severe symptom of amyotrophic lateral sclerosis (ALS), caused both from inadequate calorie intake and an increased metabolic rate. People with ALS are generally instructed to increase their calorie intake; however, the ideal amount and type of calories has not been studied. Several studies in an animal model of motor neuron disease have shown that a high fat/high calorie diet can increase survival by as much as 38%. Mice on a high fat diet also live longer than mice fed diets consisting of high protein or high sugar. We are therefore conducting a phase II safety, tolerability, and preliminary efficacy trial in ALS of high fat versus high calorie versus normal diet. The normal diet will be calculated based on the number of calories needed to replace each participant's measured daily calorie requirement.
Study Sponsor:
Massachusetts General Hospital
Participant Duration:
5 ½ months; 5 visits in clinic; 4 telephone visits. Visits last approximately 2.5 to 5 hours.
Estimated Enrollment:
28
Estimated Study Start Date:
09 / 30 / 2009
Estimated Study Completion Date:
05 / 01 / 2013
Posting Last Modified Date:
02 / 27 / 2015
Date Study Added to neals.org:
09 / 24 / 2009
Minimum Age:
18 Years
Maximum Age:
N/A
Can participants use Riluzole?
Yes
Inclusion Criteria:1. Clinical diagnosis of ALS
2. Male or female subjects aged 18 years or older
3. Must already be tolerating tube feedings through either a gastrostomy tube (G-tube or PEG) or jejunostomy tube (J-tube)
4. Must require non-invasive ventilation (BIPAP) for less than 10 hours/day
5. Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating.
Exclusion Criteria:
1. History of hepatitis including non-alcoholic steatohepatitis (NASH), cholecystectomy, prior biliary disease such as gallstones
2. History of diabetes
3. History of prior myocardial infarction or stroke
4. Laboratory values: Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.0 times the upper limit of normal or total bilirubin greater than 1.5 times the upper limit of normal
5. Allergy to soy, fish, or milk products
Barrow Neurological Institute/St. Joseph's Hospital and Medical Center
Phoenix, Arizona
85013
United States
University of California at Irvine
Irvine, California
92868
United States
California Pacific Medical Center, University of California at San Francisco
San Francisco, California
94120
United States
Sarasota Memorial Hospital
Sarasota, Florida
34239
United States
Emory University School of Medicine
Atlanta, Georgia
30322
United States
Neurology Clinical Trials Unit, Massachusetts General Hospital
Boston, Massachusetts
02114
United States
Saint Mary's Health Care
Grand Rapids, Michigan
49503
United States
Columbia Presbyterian Medical Center
New York, New York
10032
United States
Carolinas Medical Center Neuromuscular/ALS-MDA Center
Charlotte, North Carolina
28207
United States
Oregan Health and Science University
Portland, Oregon
97239
United States
Drexel University
Philadelphia, Pennsylvania
19107
United States
Methodist Neurological Institute
Houston, Texas
77030
United States
University of Vermont
Burlington, Vermont
05401
United States